Isaac Ro has 20 years of financial leadership and experience, with a strong focus on the medical technology and life sciences space. As Chief Financial Officer (CFO) at Sema4, Isaac is responsible for leading all aspects of financial strategy, management, and planning.
Prior to joining Sema4, Isaac served as CFO of Thrive Earlier Detection Corp., a company dedicated to incorporating earlier detection of cancer into routine medical care. In this capacity, he led the sale of Thrive to Exact Sciences Corp. (Nasdaq: EXAS) for $2.15 billion after rapidly scaling the company and raising $257 million in a Series B financing.
Before Thrive, Isaac led the U.S. Medical Technology team at Goldman Sachs where he covered the Life Science Tools, Diagnostics, and Medical Technology sectors. He also held a similar role at SVB Leerink. His career as an equity analyst spanned 16 years, over 60 publicly traded companies, and numerous IPOs and equity financing transactions.
Isaac holds a BA in History and was pre-med at Middlebury College.
What is Isaac Ro's net worth?
The estimated net worth of Isaac Ro is at least $572,373.00 as of August 9th, 2022. Mr. Ro owns 7,395 shares of GeneDx stock worth more than $572,373 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Ro may own. Learn More about Isaac Ro's net worth.
How do I contact Isaac Ro?
Has Isaac Ro been buying or selling shares of GeneDx?
Isaac Ro has not been actively trading shares of GeneDx over the course of the past ninety days. Most recently, Isaac Ro sold 613 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $65.67, for a transaction totalling $40,255.71. Following the completion of the sale, the chief financial officer now directly owns 7,395 shares of the company's stock, valued at $485,629.65. Learn More on Isaac Ro's trading history.
Who are GeneDx's active insiders?
Are insiders buying or selling shares of GeneDx?
In the last year, GeneDx insiders bought shares 5 times. They purchased a total of 215,804 shares worth more than $4,121,270.44. In the last year, insiders at the sold shares 45 times. They sold a total of 1,902,894 shares worth more than $108,025,448.74. The most recent insider tranaction occured on December, 16th when CEO Katherine Stueland sold 10,501 shares worth more than $805,951.75. Insiders at GeneDx own 27.3% of the company.
Learn More about insider trades at GeneDx. Information on this page was last updated on 12/16/2024.
